Document is current
Any future updates will be listed below
-
Authors
Naveen, R. https://orcid.org/0000-0003-2014-3925
Thakare, Darpan R. https://orcid.org/0000-0002-6852-4869
Kuwana, Masataka https://orcid.org/0000-0001-8352-6136
Pauling, John D. https://orcid.org/0000-0002-2793-2364
Day, Jessica https://orcid.org/0000-0001-8528-4361
Joshi, Mrudula https://orcid.org/0000-0001-7312-351X
Parodis, Ioannis https://orcid.org/0000-0002-4875-5395
Sen, Parikshit https://orcid.org/0000-0002-1630-6026
Jagtap, Kshitij https://orcid.org/0000-0003-2729-737X
Nikiphorou, Elena https://orcid.org/0000-0001-6847-3726
Saha, Sreoshy https://orcid.org/0000-0001-6745-9770
Agarwal, Vishwesh https://orcid.org/0000-0002-0986-8354
Chatterjee, Tulika https://orcid.org/0000-0001-8844-851X
Lilleker, James B. https://orcid.org/0000-0002-9230-4137
Kardes, Sinan https://orcid.org/0000-0002-6311-8634
Milchert, Marcin https://orcid.org/0000-0002-0943-8768
Gheita, Tamer https://orcid.org/0000-0002-1155-9729
Salim, Babur https://orcid.org/0000-0001-8430-9299
Velikova, Tsvetelina https://orcid.org/0000-0002-0593-1272
Gracia-Ramos, Abraham Edgar https://orcid.org/0000-0003-1842-2554
Tan, Ai Lyn https://orcid.org/0000-0002-9158-7243
Nune, Arvind https://orcid.org/0000-0002-3849-614X
Cavagna, Lorenzo https://orcid.org/0000-0003-3292-1528
Saavedra, Miguel A. https://orcid.org/0000-0003-0687-9944
Shinjo, Samuel Katsuyuki https://orcid.org/0000-0002-3682-4517
Ziade, Nelly https://orcid.org/0000-0002-4479-7678
Knitza, Johannes https://orcid.org/0000-0001-9695-0657
Distler, Oliver https://orcid.org/0000-0002-0546-8310
Chinoy, Hector https://orcid.org/0000-0001-6492-1288
,
Barman, Bhupen
Singh, Yogesh Preet
Ranjan, Rajiv
Jain, Avinash
Pandya, Sapan C.
Pilania, Rakesh Kumar
Sharma, Aman
M, Manesh Manoj
Gupta, Vikas
Kavadichanda, Chengappa G.
Patro, Pradeepta Sekhar
Ajmani, Sajal
Phatak, Sanat
Goswami, Rudra Prosad
Chowdhury, Abhra Chandra
Mathew, Ashish Jacob
Shenoy, Padnamabha
Asranna, Ajay
Bommakanti, Keerthi Talari
Shukla, Anuj
Pande, Arunkumar R.
Chandwar, Kunal
Cansu, Döndü Üsküdar
Pauling, John D.
Wincup, Chris
Makol, Ashima https://orcid.org/0000-0002-8748-898X
Del Papa, Nicoletta
Sambataro, Gianluca
Fabiola, Atzeni
Govoni, Marcello
Parisi, Simone
Bocci, Elena Bartoloni
Sebastiani, Gian Domenico
Fusaro, Enrico
Sebastiani, Marco
Quartuccio, Luca
Franceschini, Franco
Sainaghi, Pier Paolo
Orsolini, Giovanni
De Angelis, Rossella
Danielli, Maria Giovanna
Venerito, Vincenzo
Traboco, Lisa S.
Wibowo, Suryo Anggoro Kusumo
Serrano, Jorge Rojas
La Torre, Ignacio García-De
Tehozol, Erick Adrian Zamora
Loarce-Martos, Jesús
Prieto-González, Sergio
Gonzalez, Raquel Aranega
Yoshida, Akira
Nakashima, Ran
Sato, Shinji
Kimura, Naoki
Kaneko, Yuko
Tomaras, Stylianos
Gromova, Margarita Aleksandrovna
Aharonov, Or
Hmamouchi, Ihsane
Hoff, Leonardo Santos
Giannini, Margherita
Maurier, François
Campagne, Julien
Meyer, Alain
Nagy-Vincze, Melinda
Langguth, Daman
Limaye, Vidya
Needham, Merrilee
Srivastav, Nilesh
Hudson, Marie
Landon-Cardinal, Océane
Shaharir, Syahrul Sazliyana
Zuleta, Wilmer Gerardo Rojas
Silva, José António Pereira
Fonseca, João Eurico
Zimba, Olena
Aggarwal, Rohit https://orcid.org/0000-0001-7531-8038
Gupta, Latika https://orcid.org/0000-0003-2753-2990
Agarwal, Vikas https://orcid.org/0000-0002-4508-1233
Makol, Ashima https://orcid.org/0000-0002-8748-898X
- License Information
-
More Information
Article History
Received: 17 January 2023
Accepted: 7 March 2023
First Online: 31 March 2023
Declarations
:
: ALT has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, and Lilly, and holds research grants from Pfizer and Lilly. HC has received grant support from Eli Lilly and UCB, consulting fees from Novartis, Eli Lilly, Orphazyme, Astra Zeneca, speaker for UCB, and Biogen. IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG. JBL has received speaker honoraria/participated in advisory boards for Sanofi Genzyme, Roche, and Biogen. None is related to this manuscript. JD has received research funding from CSL Limited. NZ has received speaker fees, advisory board fees, and research grants from Pfizer, Roche, Abbvie, Eli Lilly, NewBridge, Sanofi-Aventis, Boehringer Ingelheim, Janssen, and Pierre Fabre; none are related to this manuscript. OD has/had consultancy relationship with and/or has received research funding from and/or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: 4P-Pharma, Abbvie, Acceleron, Alcimed, Altavant, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galderma, Galapagos, Glenmark, Gossamer, iQvia, Horizon, Inventiva, Janssen, Kymera, Lupin, Medscape, Merck, Miltenyi Biotec, Mitsubishi Tanabe, Novartis, Prometheus, Redxpharma, Roivant, Sanofi and Topadur. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143). RA has a consultancy relationship with and/or has received research funding from the following companies: Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Kyverna Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant, Merck, Galapagos, Actigraph, Scipher, Horizon Therepeutics, Teva, Beigene, ANI Pharmaceuticals, Biogen, Nuvig, Capella Bioscience, and CabalettaBio. Rest of the authors have no conflict of interest relevant to this manuscript.
: Ethical approval was obtained from the Institutional Ethics Committee of the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow, 226014.
Free to read: This content has been made available to all.
